Fundz

Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer

PRIVATEMay 31, 2023

Position

Chief Development Officer

Company

Hinge Bio

Juha Punnonen
juha.punnonen@hingebio.com
BurlingameBiotechnologyHealth CareTherapeutics

Description

Hinge Bio, Inc., a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer. Dr

Quick answer

Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer (May 31, 2023). Hinge Bio is based in Burlingame, California, United States.

Who is the new Chief Development Officer at Hinge Bio?
Hinge Bio named Juha Punnonen Chief Development Officer, announced May 31, 2023.
What did Hinge Bio announce on May 31, 2023?
Hinge Bio, Inc., a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.
What does Hinge Bio do?
Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects.
Where is Hinge Bio based?
Hinge Bio is based in Burlingame, California, United States.
Which similar companies made leadership changes around the same time?
Phanes Therapeutics (May 30, 2023), LumaBridge (May 31, 2023), Visgenx, Inc. (June 5, 2023) and Chemomab Therapeutics Ltd (June 5, 2023) also announced leadership changes within 45 days of Hinge Bio.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Hinge Bio, and when

A new leader at Hinge Bio brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Hinge Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hinge Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hinge Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Hinge Bio

Location

863 MITTEN ROAD, SUITE 100L

Burlingame, California, United States

About

Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects. The GEM-DIMER platform creates multivalent, multispecific antibody-based therapeutics that bind their targets in a novel manner allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER technology was invented by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who previously was the first to clone and express recombinant Factor VIII (Genentech) and invented Fc-fusion proteins (Genentech) as well as chimeric antigen receptors for T cell therapy/CAR-T (Cell Genesys). Dr. Capon also holds patents on the XenoMouse for the production of fully human antibodies (Abgenix) and the PhenoSense drug susceptibility and resistance test (Monogram Biosciences/LabCorp).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Hinge Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Juha
Likely contact at this company
••••••••@••••••••

See Juha's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Hinge Bio's next move

Learn about Strategic plan

Hinge Bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.